## Amendments to the Claims

1. (Currently Amended) A capsule preparation, which comprises a capsule shell and contains inside the capsule shell a medicine unstable to moisture, wherein the medicine unstable to moisture is lansoprazole or an optically active isomer thereof or a salt thereof;

the capsule preparation contains inside the capsule shell at least two solid preparations selected from fine granules and granules in combination, each of the at least two solid preparations comprises lansoprazole and has different medicine release properties, and

the capsule shell is stable in a low moisture state which is less or equal to relative humidity of about 35% and has pH-independent disintegration properties, and provided that the capsule shell excludes hard gelatin and/or hydroxypropyl methyl cellulose as a main component of the capsule shell.

## 2. (Cancelled)

- 3. (Withdrawn) The capsule preparation according to claim 1, wherein the main component of the capsule shell is a gelatin containing polyethylene glycol.
- **4.** (**Previously Presented**) The capsule preparation according to claim 1, wherein the main component of the capsule shell is a water-soluble polysaccharide.
- 5. (Previously Presented) The capsule preparation according to claim 1, wherein the main component of the capsule shell is pullulan.
- **6.** (Withdrawn) The capsule preparation according to claim 1, which combines a capsule shell comprising gelatin containing polyethylene glycol as the main component and a capsule shell comprising pullulan as the main component.

## 7-11. (Cancelled)

12. (Previously presented) The capsule preparation according to claim 1, wherein the medicine unstable to moisture is the R-isomer of lansoprazole.

- 13. (Withdrawn) The capsule preparation according to claim 1, wherein the medicine unstable to moisture is a prodrug of PPI.
- 14. (Original) The capsule preparation according to claim 1, wherein the content in the capsule is a powdered medicine.

## 15-17. (Cancelled)

- 18. (Currently amended) The capsule preparation according to claim—16\_1, wherein at least one of the eombined-solid preparations has a coating layer.
- 19. (Original) The capsule preparation according to claim 18, wherein the coating layer is an enteric coating layer.
- 20. (Original) The capsule preparation according to claim 18, wherein the coating layer contains a controlled-release coating layer.
- **21.** (**Previously Presented**) The capsule preparation according to claim 20, wherein the controlled-release coating layer is a coating layer soluble within a range of pH 6.0 to pH 7.5.
- **22.** (Original) The capsule preparation according to claim 21, wherein the controlled-release coating layer is a diffusion-control type controlled-release film.
- 23. (Original) The capsule preparation according to claim 21, wherein the controlled-release coating layer is a time release type controlled-release coating film.
- **24.** (Previously presented) The capsule preparation according to claim 1, which contains fine granules, granules or tablets having an enteric coating layer in combination with fine granules, granules or tablets having a controlled-release coating layer.